Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis – a meta-analysis of randomized clinical trials

References

• Garg N, Silverberg J. Epidemiology of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):281–288. doi: 10.1016/j.clindermatol.2014.12.004
   PubMed Web of Science ®Google Scholar
• Silverberg J. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289. doi: 10.1016/j.det.2017.02.002
   PubMed Web of Science ®Google Scholar
• Girolomoni G, de Bruin-Weller M, Aoki V, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:20406223211002979. doi: 10.1177/20406223211002979
   Web of Science ®Google Scholar
• Eichenfield LF, Stripling S, Fung S, et al. Recent developments and advances in atopic dermatitis: a focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Pediatr Drugs. 2022;24(4):293–305. doi: 10.1007/s40272-022-00499-x
   PubMed Web of Science ®Google Scholar
• Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35(3):317–326. doi: 10.1016/j.det.2017.02.006
   PubMed Web of Science ®Google Scholar
• Schuler CF, Billi AC, Maverakis E, et al. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145–1154. doi: 10.1016/j.jaci.2022.10.023
   PubMed Web of Science ®Google Scholar
• Clebak KT, Helm L, Uppal P, et al. Atopic dermatitis. Prim Care - Clin Off Pract. 2023;50(2):191–203. doi: 10.1016/j.pop.2022.12.004
   PubMed Web of Science ®Google Scholar
• Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858–873. doi: 10.3390/jcm4050858
   PubMed Web of Science ®Google Scholar
• Napolitano M, di Vico F, Ruggiero A, et al. The hidden sentinel of the skin: an overview on the role of interleukin-13 in atopic dermatitis. Front Med. 2023;10:1–7. doi: 10.3389/fmed.2023.1165098
   Web of Science ®Google Scholar
• Salvati L, Cosmi L, Annunziato F. Molecular sciences review from emollients to biologicals: targeting atopic dermatitis. Dermatitis Int J Mol Sci. 2021;22(19):1–13. doi: 10.3390/ijms221910381
   Web of Science ®Google Scholar
• Calabrese G, Licata G, Gambardella A, et al. Topical and conventional systemic treatments in atopic dermatitis: have they gone out of fashion? Dermatology Pract Concept. 2022;12:1–5. doi: 10.5826/dpc.1201a155
   Google Scholar
• van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;1–426.
   Web of Science ®Google Scholar
• Freitas E, Gooderham M, Torres T. New topical therapies in development for atopic dermatitis. Drugs. 2022;82(8):843–853. doi: 10.1007/s40265-022-01722-2
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
   PubMed Web of Science ®Google Scholar
• Agache I, Song Y, Posso M, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy: Eur J Allergy Clin Immunol. 2021;76(1):45–58. doi: 10.1111/all.14510
   Google Scholar
• Eyerich S, Metz M, Bossios A, et al. New biological treatments for asthma and skin allergies. Allergy: Eur J Allergy Clin Immunol. 2020;75(3):546–560. doi: 10.1111/all.14027
   Google Scholar
• Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis update of a Living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–532. doi: 10.1001/jamadermatol.2022.0455
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Weidinger S, Worm M, et al. Tralokinumab in atopic dermatitis. JDDG - J Ger Soc Dermatol. 2021;19(10):1435–1442. doi: 10.1111/ddg.14545
   Web of Science ®Google Scholar
• Blair HA. Tralokinumab in atopic dermatitis: a profile of its use. Clin Drug Investig. 2022;42(4):365–374. doi: 10.1007/s40261-022-01135-9
   PubMed Web of Science ®Google Scholar
• Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338–352. doi: 10.1111/bjd.21630
   PubMed Web of Science ®Google Scholar
• Mikhaylov D, Ungar B, Renert-Yuval Y, et al. Oral janus kinase inhibitors for atopic dermatitis. Ann Allergy Asthma Immunol. 2023;130(5):577–592. doi: 10.1016/j.anai.2023.01.020
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the Current evidence. JID Innov. 2023;3(3):100195. doi: 10.1016/j.xjidi.2023.100195
   PubMedGoogle Scholar
• Napolitano M, Fabbrocini G, Martora F, et al. Children atopic dermatitis: diagnosis, mimics, overlaps, and therapeutic implication. Dermatol Ther. 2022;35(12):1–9. doi: 10.1111/dth.15901
   Web of Science ®Google Scholar
• Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi: 10.1097/ACI.0000000000000837
   PubMed Web of Science ®Google Scholar
• Stingeni L, Bianchi L, Antonelli E, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022;36(8):1292–1299. doi: 10.1111/jdv.18141
   PubMed Web of Science ®Google Scholar
• Yue H, Umehara Y, Trujillo-Paez JV, et al. Exogenous factors in the pathogenesis of atopic dermatitis: irritants and cutaneous infections. Clin Exp Allergy. 2021;51(3):382–392. doi: 10.1111/cea.13820
   PubMed Web of Science ®Google Scholar
• Mastorino L, Rosset F, Gelato F, et al. Chronic pruritus in atopic patients treated with Dupilumab: real life response and related parameters in 354 patients. Pharmaceuticals. 2022;15(7):883. doi: 10.3390/ph15070883
   Web of Science ®Google Scholar
• Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(2):e239–e242. doi: 10.1111/j.1468-3083.2012.04578.x
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66. doi: 10.1038/jid.2014.325
   PubMed Web of Science ®Google Scholar
• Miniotti M, Ribero S, Mastorino L, et al. Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: data up to 3 years. Exp Dermatol. 2023;32(6):852–858. doi: 10.1111/exd.14786
   PubMed Web of Science ®Google Scholar
• Wan J, Shin DB, Syed MN, et al. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study*. Br J Dermatol. 2022;186(4):664–672. doi: 10.1111/bjd.20887
   PubMed Web of Science ®Google Scholar
• Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a Comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329–337. doi: 10.1007/s12016-016-8548-5
   PubMed Web of Science ®Google Scholar
• Alexander HD, Paller ASD, Traidl-Hoffmann CD, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International eczema Council skin infection group. Br J Dermatol. 2020;182(6):1331–1342. doi: 10.1111/bjd.18643
   PubMed Web of Science ®Google Scholar
• Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69.e1. doi: 10.1016/j.jaad.2017.09.052
   PubMed Web of Science ®Google Scholar
• Ou Z, Chen C, Chen A, et al. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303–310. doi: 10.1016/j.intimp.2017.11.031
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009 Jul 21;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139. doi: 10.1056/NEJMoa1314768
   PubMed Web of Science ®Google Scholar
• Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol. 2018;178(2):406–414. doi: 10.1111/bjd.15905
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi: 10.1016/j.jaci.2018.08.022
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis. A phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. doi: 10.1001/jamadermatol.2019.3336
   PubMed Web of Science ®Google Scholar
• Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131–143. doi: 10.1001/jamadermatol.2019.3617
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Romagnuolo M, Maronese CA, et al. Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis. Ther Adv Chronic Dis. 2021;12:1–8. doi: 10.1177/20406223211058332
   Web of Science ®Google Scholar
• Cristaudo A, Pigliacelli F, Sperati F, et al. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: an observational study. Ski Res Technol. 2021;27(5):810–813. doi: 10.1111/srt.13025
   PubMed Web of Science ®Google Scholar
• Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy: Eur J Allergy Clin Immunol. 2022;77(11):3388–3397. doi: 10.1111/all.15432
   Google Scholar
• Rohner MH, Thormann K, Cazzaniga S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy: Eur J Allergy Clin Immunol. 2021;76(4):1268–1270. doi: 10.1111/all.14664
   Google Scholar
• Paller AS, Beck LA, Blauvelt A, et al. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data. Pediatr Dermatol. 2022;39(2):187–196. doi: 10.1111/pde.14909
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi: 10.1016/j.jaad.2020.06.054
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Simpson EL, et al. Dupilumab with topical corticosteroids provides rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across anatomic regions over 52 weeks. Dermatol Ther (Heidelb). 2022;12(1):223–231. doi: 10.1007/s13555-021-00638-1
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Cash K. Topical corticosteroid application and the structural and functional integrity of the epidermal barrier. J Clin Aesthet Dermatol. 2013;6:20–27.
   Google Scholar
• Mooney E, Rademaker M, Dailey R, et al. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Australas J Dermatol. 2015;56(4):241–251. doi: 10.1111/ajd.12313
   PubMed Web of Science ®Google Scholar
• Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992;27(1):29–34. doi: 10.1016/0190-9622(92)70151-5
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456. doi: 10.1007/s40257-019-00445-7
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J DermatolTreat. 2022;33(7):3028–3033. doi: 10.1080/09546634.2022.2102121
   Google Scholar
• Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. doi: 10.1016/j.jaip.2022.05.019
   PubMed Web of Science ®Google Scholar
• Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. doi: 10.1056/NEJMoa2205982
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):17–20. doi: 10.1111/dth.15120
   Web of Science ®Google Scholar